Cormorant Asset Management, LLC
Q4 2013 13F-HR Holdings
Net value change ($000)
—
New positions
37
Sold out positions
0
Turnover %
100.0%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to previous filing: —
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| MEDIVATION | 34,903 | — |
| CUBIST PHARMACEUTICALS INC | 27,548 | — |
| KERYX BIOPHARMACEUTICALS | 22,015 | — |
| DYAX CORP | 21,475 | — |
| PBYI | 20,706 | — |
| CELG | 20,276 | — |
| ACAD | 19,992 | — |
| IDENIX PHARMACEUTICALS INC | 17,492 | — |
| GERN | 16,103 | — |
| ALNY | 16,075 | — |
Top Reduces (Value $000, Stocks/ETFs)
| — |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|